89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
September 21, 2023 08:00 ET
|
89bio, Inc.
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the...
89bio to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 16:01 ET
|
89bio, Inc.
– Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress – –...
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2023 16:30 ET
|
89bio, Inc.
SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
June 24, 2023 05:05 ET
|
89bio, Inc.
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3...
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
June 24, 2023 05:01 ET
|
89bio, Inc.
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2023 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
June 07, 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
May 23, 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...